Novartis’s Chinook takeout gives a boost to others pursuing this long-researched target, including Vera and Alpine.
After Calliditas and Travere secure US approvals Novartis doubles down on a rare kidney disease, but what will the FTC say?
Chinook, Vertex and Dimerix are following Travere in FSGS, but several dropouts point to challenges in this disease.
Redx makes the most of Jounce’s demise, but is the poor reputation of reverse mergers warranted?
Atacicept hits in phase 2, but uncompetitive data are seen as good news for its IgAN rivals.
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.